Comments
FDA staff sends mixed message on J&J drug Xarelto
22.05.2012. | WASHINGTON (Reuters) - U.S. drug reviewers had mixed opinions about whether Johnson & Johnson blood thinner Xarelto reduced the risk of new heart attacks and strokes in people with heart problems, setting the stage for heated debate by outside experts later this week....
